A new long-acting testosterone therapy has been approved by the Food and Drug Administration (FDA), but the approval comes with a black box warning and strong prescribing restrictions. Aveed, made by Endo Pharmaceuticals, is a long-acting depot formulation of testosterone in caster oil and benzyl benzoate. It is administered in a single 3-mL (750 mg) intramuscular injection given once at initiation of therapy, at four weeks after initiation of treatment, and then every 10 weeks thereafter. Aveed is approved to treat hypogonadism, a condition in which men produce too little of the hormone due to disease or defect. The FDA required ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.